BlackRock ETF Trust II BlackRock Short-Term California Muni Bond ETF CALY 深 沪
等待开盘 08-06 09:30:00 美东时间
50.375
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 50.375
- 总市值 2015.00万
- 52周最高 49.5102
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 46.973
- 委 比 0.00%
- 总股本 40.00万
- 历史最高 49.5102
- 量 比 0
- 振 幅 0.00%
- 历史最低 47.0906
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q2 earnings call. R...
07-30 08:38
美联储放“鸽”！纳指生物科技ETF(513290)放量涨超1%，美股创新药并购火热！阿斯利康豪掷10亿美元，进军CGT赛道
3月20日，纳指生物科技ETF（513290）盘中涨超1%，冲击三连涨，刷新近15个月以来新高！成交额超5700万元，环比放量！ 当地时间周三（3月19日）...
03-20 13:57
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for small cell lung cancer treatment.
03-17 19:58
Kiniksa Expects 2025 Arcalyst Net Product Revenue Of Between $560M-$580M
Financial GuidanceKiniksa expects 2025 ARCALYST net product revenue of between $560 million and $580 million.Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
02-25 20:36
Kiniksa Pharmaceuticals reports preliminary 2024 net product revenue of $416.4 million
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) on Monday reported preliminary ARCALYST net product revenue of $121.9 million for the fourth quarter, compared to consensus revenue estimates of 123...
01-13 20:52
Kiniksa Pharma Reports Q4 ARCALYST Revenue Of $121.9M, Cash Balance Of $243.6M
Commercial ExecutionARCALYST (IL-1α and IL-1β cytokine trap)ARCALYST net product revenue was $121.9 million and $416.4 million for the fourth quarter and full year 2024, respectively (unaudited).As of the end of the
01-13 20:40
Kiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlook
Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q1 GAAP EPS of -$0.25 misses by $0.09. Revenue of $79.86M (+65.2% Y/Y) beats by $1.4M. As of March 31, 2024, Kiniksa had $213.6 million of cash, ca...
2024-04-23 19:37
Kiniksa Pharmicalsa 提供公司最新情况
– ARCALYST (rilonacept) 2023 net product revenue grew ~90% year-over-year to $2...
2024-01-04 20:30
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, L...
2024-01-03 05:01
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, L...
2023-07-17 20:00
